Navigation Links
CryoLife to Present at 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference
Date:11/29/2011

ATLANTA, Nov. 29, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference on Tuesday, December 6, 2011 at the St. Regis Hotel in San Francisco.

D. Ashley Lee, executive vice president, chief operating office, and chief financial officer of CryoLife, Inc., is scheduled to present at 1:40 p.m. PT.  

CryoLife's live presentation may be accessed through its website, www.cryolife.com, on the Investor Relations page.  An archived copy of the presentation will be available for 90 days on the same website.

About CryoLifeFounded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of cardiovascular disease and the sale of devices that treat severe angina.  Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community.  CryoLife's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  

For additional information about the company, visit CryoLife's website:
http://www.cryolife.com.Contacts:CryoLife

D. Ashley Lee
Executive Vice President, Chief Financial Officer
 and Chief Operating Officer
Phone: 770-419-3355

The Ruth Group
Nick Laudico / Zack Kubow
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife to Present at 23rd Annual Piper Jaffray Health Care Conference
2. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CryoLife Announces Release Date and Teleconference Call Details for 2011 Third Quarter Financial Results
5. CryoLife Provides Update on ValveXchange®, Inc. Investment
6. CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
7. CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
8. CryoLife Makes Equity Investment in ValveXchange® Inc.
9. CryoLife Announces Completion of Acquisition of Cardiogenesis
10. CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
11. CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... James Gilbart , ... 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... recently in a supplement to European Oncology & ... article by James Gilbart and ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange ... excited to announce that the first five replication ...  (RP:CB) have been published in eLife today. Despite ... represents the first practical evaluation of reproducibility rates ... reproducible studies. Unlike other assessments of reproducibility, the ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that ... product to the United States as part of its presence to expand its market ... aims to reduce the productions of nasty toxins as a result of drinking alcohol, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take ... rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, ... Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... new medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two ...
(Date:1/20/2017)... ... ... Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift ... can be wheeled out of the way and stored when not in use. It is ... the feedback from customers into specific enhancements and created a new product that is built ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a ... percent pure essential oils, announced the company had a successful visit to the 2017 ... ECRM event gives companies that work in the nutritional, sports and health industries a ...
Breaking Medicine News(10 mins):